NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

非典型畸胎瘤樣橫紋肌樣瘤:2021年的開發平台趨勢

Atypical Teratoid Rhabdoid Tumors - Pipeline Insght, 2021

出版商 DelveInsight Business Research LLP 商品編碼 1023375
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 2-10個工作天內
價格
非典型畸胎瘤樣橫紋肌樣瘤:2021年的開發平台趨勢 Atypical Teratoid Rhabdoid Tumors - Pipeline Insght, 2021
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

本報告提供非典型畸胎瘤樣橫紋肌樣瘤的目前方案與成長預測的整體性洞察。非典型畸胎瘤樣橫的開發平台詳細狀況,疾病概要和非典型畸胎瘤樣的治療指南等記載。評估的部分,非典型畸胎瘤樣橫紋肌樣瘤的商業性評估和開發中的開發中產品的臨床性評估。還有藥物的詳細說明,藥物的作用機制,臨床試驗,NDA核準(如果有),包含技術的產品開發活動,非典型畸胎瘤樣橫紋肌樣瘤的共同研究,授權,合併、收購,資金籌措,指定,其他的產品相關記載的詳細內容。

目錄

  • 原因
  • 作用機制
  • 症狀
  • 診斷
  • 疾病管理
  • 比較分析
  • 產品類型的評估
  • 各階段及各產品類型評估
  • 各給藥途徑評估
  • 給藥的階段與各途徑評估
  • 各分子類型評估
  • 各階段及各分子類型評估
  • 比較分析
  • 產品說明
  • 研究開發
  • 產品開發活動
  • 比較分析
  • 產品說明
  • 研究開發
  • 產品開發活動
  • 比較分析
  • 產品說明
  • 研究開發
  • 產品開發活動
  • 比較分析
目錄
Product Code: DIPI0975

DelveInsight's, "Atypical Teratoid Rhabdoid Tumors - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atypical Teratoid Rhabdoid Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Atypical Teratoid Rhabdoid Tumors Understanding

Atypical Teratoid Rhabdoid Tumors: Overview

An atypical teratoid rhabdoid tumor (ATRT) is a very rare, aggressive tumor of the central nervous system, occurring mostly in the cerebellum, the part of the brain that controls movement and balance, or the brain stem, the part of the brain that controls basic body functions. ATRTs usually occur by age 3, but sometimes are found in older children. ATRTs represent only 1 to 2 percent of childhood brain tumors. These tumors are part of a larger group of malignant tumors called rhabdoid tumors, which also can occur outside the brain. ATRTs may be localized to one part of the brain, or they can spread to other locations in the brain, spine or body. Most ATRTs are caused by changes in a gene known as SMARCB1 (also called INI1). This gene normally signals proteins to stop tumor growth. But in ATRTs, SMARCB1 doesn't function properly and tumor growth is uncontrolled. The signs and symptoms of atypical teratoid rhabdoid tumor varies with patient to patient and depend on the child's age as well as tumor location. A diagnosis of typical Teratoid Rhabdoid Tumors (ATRT) is based upon a thorough clinical evaluation, and a variety of specialized tests. ATRT is most commonly diagnosed from imaging studies like Magnetic resonance imaging (MRI), Computerized tomography scan, Lumbar puncture, Ultrasound, and biopsy. Treatment of ATRT mainly includes surgery, chemotherapy or radiation therapy. Combinatorial treatment of surgical resection, chemotherapy, and radiation therapy is widely used. Multiple clinical trials testing molecularly targeted therapies are underway.

"Atypical Teratoid Rhabdoid Tumors - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atypical Teratoid Rhabdoid Tumors pipeline landscape is provided which includes the disease overview and Atypical Teratoid Rhabdoid Tumors treatment guidelines. The assessment part of the report embraces, in depth Atypical Teratoid Rhabdoid Tumors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Atypical Teratoid Rhabdoid Tumors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

  • The companies and academics are working to assess challenges and seek opportunities that could influence Atypical Teratoid Rhabdoid Tumors R&D. The therapies under development are focused on novel approaches to treat/improve Atypical Teratoid Rhabdoid Tumors.

Atypical Teratoid Rhabdoid Tumors Emerging Drugs Chapters

This segment of the Atypical Teratoid Rhabdoid Tumors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atypical Teratoid Rhabdoid Tumors Emerging Drugs

  • Tazemetostat: Epizyme

Tazemetostat is an orally administered, first-in-class small molecule EZH2 inhibitor, for the treatment of multiple types of hematological malignancies and genetically defined solid tumors. In early clinical development, tazemetostat has demonstrated clinical activity and a generally well-tolerated safety profile in both patients with hematological malignancies and genetically defined solid tumors. Epizyme is investigating tazemetostat for Atypical Teratoid Rhabdoid Tumors and is currently in phase II stage of development.

  • Alisertib: Takeda

Alisertib selectively binds to and inhibits Aurora A kinase in cells. Inhibition of Aurora A results in delayed mitotic entry and progression through mitosis leading to an accumulation of cells with a tetraploid DNA content. The drug is being evaluated either alone or in combination with other chemotherapy agents in Phase II clinical trial to treat patients with Atypical Teratoid Rhabdoid Tumors.

Further product details are provided in the report……..

Atypical Teratoid Rhabdoid Tumors: Therapeutic Assessment

This segment of the report provides insights about the different Atypical Teratoid Rhabdoid Tumors drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Atypical Teratoid Rhabdoid Tumors

There are approx. 10+ key companies which are developing the therapies for Atypical Teratoid Rhabdoid Tumors. The companies which have their Atypical Teratoid Rhabdoid Tumors drug candidates in the most advanced stage, i.e. Phase II include, Epizyme.

  • Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Atypical Teratoid Rhabdoid Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atypical Teratoid Rhabdoid Tumors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atypical Teratoid Rhabdoid Tumors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atypical Teratoid Rhabdoid Tumors drugs.

Atypical Teratoid Rhabdoid Tumors Report Insights

  • Atypical Teratoid Rhabdoid Tumors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Atypical Teratoid Rhabdoid Tumors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Atypical Teratoid Rhabdoid Tumors drugs?
  • How many Atypical Teratoid Rhabdoid Tumors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atypical Teratoid Rhabdoid Tumors?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atypical Teratoid Rhabdoid Tumors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Atypical Teratoid Rhabdoid Tumors and their status?
  • What are the key designations that have been granted to the emerging drugs?

Table of Contents

Introduction

Executive Summary

Atypical Teratoid Rhabdoid Tumors: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Tazemetostat: Epizyme

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early stage products (Phase I)

  • Comparative Analysis

ONC206: Chimerix

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Atypical Teratoid Rhabdoid Tumors Key Companies

Atypical Teratoid Rhabdoid Tumors Key Products

Atypical Teratoid Rhabdoid Tumors- Unmet Needs

Atypical Teratoid Rhabdoid Tumors- Market Drivers and Barriers

Atypical Teratoid Rhabdoid Tumors- Future Perspectives and Conclusion

Atypical Teratoid Rhabdoid Tumors Analyst Views

Atypical Teratoid Rhabdoid Tumors Key Companies

Appendix

List of Tables

  • Table 1 Total Products for Atypical Teratoid Rhabdoid Tumors
  • Table 2 Late Stage Products
  • Table 3 Mid Stage Products
  • Table 4 Early Stage Products
  • Table 5 Pre-clinical & Discovery Stage Products
  • Table 6 Assessment by Product Type
  • Table 7 Assessment by Stage and Product Type
  • Table 8 Assessment by Route of Administration
  • Table 9 Assessment by Stage and Route of Administration
  • Table 10 Assessment by Molecule Type
  • Table 11 Assessment by Stage and Molecule Type
  • Table 12 Inactive Products

List of Figures

  • Figure 1 Total Products for Atypical Teratoid Rhabdoid Tumors
  • Figure 2 Late Stage Products
  • Figure 3 Mid Stage Products
  • Figure 4 Early Stage Products
  • Figure 5 Preclinical and Discovery Stage Products
  • Figure 6 Assessment by Product Type
  • Figure 7 Assessment by Stage and Product Type
  • Figure 8 Assessment by Route of Administration
  • Figure 9 Assessment by Stage and Route of Administration
  • Figure 10 Assessment by Molecule Type
  • Figure 11 Assessment by Stage and Molecule Type
  • Figure 12 Inactive Products